Is premarket identification of hepatotoxic drugs and sensitive patients possible based on high-dimensional 'omic data?

Personalized Medicine

Volumn 7, Issue 2, 2010, Pages 171-178

  Kodell, Ralph L ^a   Chen, James J ^b  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

Author keywords

Biomarker; Genomic; Idiosyncratic liver toxicity; Personalizedmedicine; Population heterogeneity; Proteomic; Selective voting

Indexed keywords

BIOLOGICAL MARKER;

DRUG MARKETING; FOOD AND DRUG ADMINISTRATION; HEALTH SERVICE; LIVER TOXICITY; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

EID: 77949732404     PISSN: 17410541     EISSN: 1744828X     Source Type: Journal    
DOI: 10.2217/pme.10.7     Document Type: Review

References (12)

1. Kaplowitz N: Idiosyncratic drug hepatotoxicity. Nat. Rev. Drug Discov. 4, 489-499 (2005).
2. Boelsterli UA: Diclofenac-induced livery injury: a paradigm of idiosyncratic drug toxicity. Toxicol. Appl. Pharmacol. 192, 307-322 (2003).
3. Tsong Y: Postmarketing adverse drug event signaling. In: Encyclopedia of Biopharmaceutical Statistics. Marcel Dekker, Inc., NY, USA, 776-789 (2003).
4. Brind AM: Drugs that damage the liver. Medicine 35, 26-30 (2007).
5. Goldberg P: KRAS finding changes oncology practice but poses profound regulatory dilemma. The Cancer Letter 35(4), 1-8 (2009).
6. Whitehead J, Kelly P, Zhou Y, Stallard N, Thygesen H, Bowman C: Action following the discovery of a global association between the whole genome and adverse event risk in a clinical drug-development programme. Pharm. Stat. 8(4), 287-300 (2008).
7. Polikar R: Ensemble based systems in decision making. IEEE Circ. Sys. Mag. 6, 21-45 (2006).
8. Lukaszyk S: A new concept of probability metric and its applications in approximation of scattered data sets. Comput. Mech. 33, 299-304 (2004).
9. Eisen MB, Spellman PT, Brown PO, Botstein D: Cluster analysis and display of genome-wide expression patterns. Proc. Natl Acad. Sci. USA 95, 14863-14868 (1998).
10. Kodell RL, Pearce BA, Baek S et al.: A model-free ensemble method for class prediction with application to biomedical decision making. Artif. Intell. Med. 46, 267-276 (2009).
11. Gaylor DW: Risk/benefit assessments of human diseases: optimum dose for intervention. Risk Anal. 25, 161-168 (2005).
12. King-Herbert A, Thayer K: NTP workshop: Animal models for the NTP rodent cancer bioassay: stocks and strains - should we switch? Toxicol. Pathol. 34, 802-805 (2006).